| REVIEW ARTICLE |
|
| Year : 2022 | Volume
: 12
| Issue : 2 | Page : 78-85 |
|
|
Systemic medications and implant success: Is there a link? Part three: The effects of antiresorptive and anti-angiogenic agents on the outcome of implant therapy
Prema Sukumaran1, Dionetta Delitta Dionysius2, Wei Cheong Ngeow3, Chuey Chuan Tan3, Mohd Zamri Hussin4
1 Faculty of Dentistry, Oral & Craniofacial Sciences, King's College London, England
2 Department of Oral and Maxillofacial Surgery, Hospital Sutanah Nora Ismail, Johor, Malaysia
3 Department of Oral and Maxillofacial Clinical Sciences, Faculty of Dentistry, University Malaya, Kuala Lumpur, Malaysia
4 Departments of Restorative Dentistrym Faculty of Dentistry, University Malaya, Kuala Lumpur, Malaysia
Correspondence Address:
Dr. Prema Sukumaran
Centre for Oral, Clinical and Translational Sciences, King's College London
England
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jdi.jdi_24_21
|
|
|
Dental implants require healthy bone for successful osseointegration. However, bone health can become compromised by aging and/or the presence of underlying medical conditions. The severity and complications associated with these medical conditions usually indicate that they require medication for successful management. Some of these medications may undoubtedly exert effects on bone through direct or indirect mechanisms and, therefore, may also affect osseointegration. These include antihypertensive drugs, oral hypoglycemic agents/insulin, hormones (corticosteroid, thyroxin, and tamoxifen), and antiresorptive agents, including bisphosphonates and anti-angiogenic agents. Part three of this paper reviews the current knowledge regarding the effects of antiresorptive agents on the outcome of implant therapy.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
